Population pharmacokinetics of Pseudechis porphyriacus (red-bellied black snake) venom in snakebite patients

• Published in: Clinical toxicology (Philadelphia, Pa.) Vol. 59; no. 11; pp. 956 - 962
• Main Authors: Sanhajariya, Suchaya, Duffull, Stephen B., Isbister, Geoffrey K.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.11.2021
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antivenins - administration & dosage; antivenom; Child; Child, Preschool; Drug Administration Schedule; Elapid Venoms - antagonists & inhibitors; Elapid Venoms - blood; Elapid Venoms - pharmacokinetics; Elapidae; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; pharmacokinetics; Pseudechis porphyriacus; red-bellied black snake; Snake Bites - blood; Snake Bites - diagnosis; Snake Bites - drug therapy; Snake venom; Treatment Outcome; Young Adult; pharmacokinetics; Pseudechis porphyriacus; red-bellied black snake; Snake venom; antivenom
• ISSN: 1556-3650; 1556-9519; 1556-9519
• DOI: 10.1080/15563650.2021.1896731

Understanding the time course of venom exposure in snakebite patients is important for the optimisation of treatment including antivenom dose and timing. We aimed to investigate the pharmacokinetics of red-bellied black snake (RBBS; Pseudechis porphyriacus) venom in envenomed patients. Timed venom concentration data were obtained from patients with RBBS envenomation recruited to the Australian Snakebite Project (ASP), including demographics and antivenom treatment. Venom concentrations were measured using an enzyme immunoassay. Data were modelled using NONMEM version 7.3. Uncertainty in venom "dose" was accounted for by arbitrarily fixing the average amount to 1 mg and incorporating between-subject variability on relative bioavailability. A scale parameter for venom clearance was implemented to account for the rapid venom clearance following antivenom dosing. A sensitivity analysis was performed to determine the magnitude of venom clearance amplification. There were 457 venom concentrations in 114 patients (median age 41, 2-90 y; 80 male). Antivenom was administered to 54 patients a median of 4.2 h post-bite (0.67 to 32 h). A one-compartment model with first-order absorption and elimination provided the best description of the data. The estimated clearance and volume of distribution were 5.21 L/h and 39.9 L, respectively. The calculated elimination half-life of P. porphyriacus venom from the final pharmacokinetic model was 5.35 ± 0.36 h. The variability in the relative dose of injected venom was 140%. Antivenom administration increased venom clearance by 40-fold. Ten patients showed evidence of a double peak in the absorption profile. The information on the exposure time of venom in the body following envenomation will help improve treatment and the timing of antivenom.